Cell Therapeutics, Inc. (CTI) Readies Pixuvri® European Launch and Start of ... MarketWatch (press release) The European Medicines Agency's (the "EMA") Committee for Medicinal Products for Human Use has accepted PIX306, CTI's ongoing randomized controlled phase III clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in patients who ... |
